Company / R&D Expense
Zoetis R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$698.0M
FY2025
5-year range
$457.0M / $698.0M
FY2021-FY2025
Trend
+1.7%
vs FY2024
Sector context
#28 of 210
Health Care
What the data says
Zoetis's r&d expense of $698M is higher than 87% of companies in the Health Care sector (FY2025). R&D Expense has increased for 5 consecutive years, from $432M in FY2020 to $698M in FY2025.
Based on SEC 10-K filings.
$698M in FY2025 with a 5-year CAGR of +10.1%. Top quartile in the Health Care sector.
Improved from $508M to $698M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +14.7%
- 5-Year CAGR
- +10.1%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 210This company $698.0M Sector average $644.1M
▼
+8.4% above sector average
Key checks
Key Insights
- Zoetis's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +10.1%, indicating consistent growth.
- In FY2025, r&d expense increased 1.7% year-over-year.
- Ranks #28 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 28.2%
- Strong return on equity: 49.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $698.0M | +1.7% |
| FY2024 | $686.0M | +35.0% |
| FY2023 | $508.0M | +9.7% |
| FY2022 | $463.0M | +1.3% |
| FY2021 | $457.0M | +5.8% |
| FY2020 | $432.0M | -5.5% |
| FY2019 | $457.0M | +5.8% |
| FY2018 | $432.0M | +18.7% |
| FY2017 | $364.0M | -8.1% |
| FY2016 | $396.0M | -0.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026